Zurück zu Ihrem Suchergebnis

Beschreibung

Wild-type, human Abeta1-42 peptide. This product is supplied in a form that is not neurotoxic prior to a pre-incubation step. The level of toxicity has been shown to correlate to the extent of beta sheet structure., Wild-type, human Abeta1-42 peptide. A number of mutations, identified in the gene encoding the beta-amyloid precursor protein (betaAPP), have been linked to early-onset Familial Alzheimer's Disease. Mutations in the genes encoding presenilin 1 and presenilin 2 have also been shown to alter the processing of betaAPP, resulting in increased extracellular concentration of beta-amyloid peptide Abeta1-42(43) relative to Abeta1-40. Biophysical and biochemical experiments suggest that Abeta1-42(43) may serve as a catalyst for the aggregation and deposition of beta-amyloid peptide (Abeta) leading to neurotoxic effects associated with senile plaque formation. Furthermore, antibodies recog-nizing Abeta1-42 revealed that the long form of the peptide is increased in presenilin and betaAPP mutants, while other studies have used Abeta specific antibodies to prevent the in vitro fibrillar aggregation of Abeta. Amino acid sequence verified by amino acid analysis or sequencing. This product is supplied in a form that is not neurotoxic prior to a preincubation step. The appearance of toxicity has recently been shown to correlate to the extent of beta sheet structure. Useful for neurotoxicity studies and substrate cleavage assays.